Tom 10, Nr 1 (2017)
Artykuł przeglądowy
Opublikowany online: 2017-04-04
Wyświetlenia strony
470
Wyświetlenia/pobrania artykułu
5152
Postępowanie z dziećmi chorymi na hemofilię powikłaną inhibitorem
Journal of Transfusion Medicine 2017;10(1):12-18.
Streszczenie
Wystąpienie inhibitora przeciwko preparatom koncentratów czynników krzepnięcia VIII lub
IX podawanym w trakcie leczenia chorych na hemofilię A lub B jest poważnym powikłaniem
choroby. Obecność inhibitora jest przyczyną braku skuteczności zastosowanego leczenia substytucyjnego,
dlatego w leczeniu hemofilii powikłanej inhibitorem hamowanie krwawień stanowi
cel doraźny, natomiast celem podstawowym jest trwała eliminacja inhibitora. W artykule
przedstawiono postępowanie w przypadku dzieci chorych na hemofilię powikłaną inhibitorem.
Słowa kluczowe: hemofiliainhibitorwywoływanie tolerancji immunologicznej (ITI)dzieci
Referencje
- Valentino LA, Pipe SW, Tarantino MD, et al. Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia. 2012; 18(3): 332–338.
- Ananyeva NM, Lacroix-Desmazes S, Hauser CAE, et al. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis. 2004; 15(2): 109–124.
- Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992; 339(8793): 594–598.
- Carcao M, Re W, Ewenstein B. The role of previously untreated patient studies in understanding the development of FVIII inhibitors. Haemophilia. 2016; 22(1): 22–31.
- Gouw SC, van der Bom JG, Ljung R, et al. PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013; 368(3): 231–239.
- Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010; 8(6): 1256–1265.
- Franchini M, Coppola A, Rocino A, et al. ; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost. 2013; 39(7): 752–766.
- Peyvandi F, Mannucci PM, Garagiola I, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016; 374(21): 2054–2064.
- Windyga J, Chojnowski K, Klukowska A, et al. Zasady postępowania w hemofilii A i B powikłanej inhibitorem. Acta Haematol. , 2008; 39. ; 3: 565–578.
- Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia. 2006; 12 Suppl 6: 48–52; discussion 52.
- Ragni M.V., Dimchele M., Hay C.M et al.: Thrombin generation and bleeding in haemophilia inhibitor patents during immune tolerance induction. Haemophilia 2016:22,240-247.
- Teitel J, Berntorp E, Dolan G, et al. A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients. Haemophilia. 2011; 17(3): 516–521.
- Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007; 109(2): 546–551.
- Schneiderman J, Nugent DJ. G. Young. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors 2004,10. ; 4: 347–351.
- Schneiderman J, Rubin E, Nugent DJ, et al. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia. 2007; 13(3): 244–248.
- Rocino A, Papa ML, Salerno E, et al. Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia. 2001; 7(1): 33–38.
- Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res. 1984; 150: 181–195.
- Mariani G, Kroner B. International immune tolerance registry, 1997 update. Vox Sang. 1999; 77 Suppl 1: 25–27.
- Lenk H. ITT Study Group. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica. 2000; 85(10 Suppl): 45–47.
- Damiano ML, Hutter JJ. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri-Regional Nursing Group. Haemophilia. 2000; 6(5): 526–532.
- Astermark J, Morado M, Rocino A, et al. EHTSB. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006; 12(4): 363–371.
- IITI. International, Randomized, Controlled Trial of Immune-tolerance Induction. Available at: http://www.itistudy.com
- Dolgin E. Immunology: Oral solutions. Nature. 2014; 515(7528): S166–S167.
- Markusic DM, Hoffman BE, Perrin GQ, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med. 2013; 5(11): 1698–1709.
- Escuriola-Ettingshausen C, et al. Martinez Saguer I. Funk M.B. : Long-term prophylaxiswith FEIBA® in patients with high-responding inhibitors. J Thromb Haemost. 2003; 1(Suppl): P1628.
- Ewing N.: Anamnestic responses in hemophilia patients with inhibitors un continuous prophylaxis with factor eight inhibitor bypassing activity, vapor heated (FEIBA VH). J. Thromb. Haemost., 2005; 3(Suppl.1): P2036.
- Kreuz W., Escuriola-Ettingshausen C., Martinez I. et al.: Efficacy and safety of factor VIII inhibitor bypass activity (Feiba)for long-term prophylaxis in patients with high-responding inhibitors. Blood, 2000; 96: 1140.
- Lambert T., Fressinaud E., Goudemand J. et al.: Can long-term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitor? Haemophilia, 2006; 12(Suppl. 2): 14 PO 399.
- Saxena K, et al. Hawk S. Stevens B. : Long-term clinical experience with FEIBA VH in hemophilia patients with inhibitors. J Thromb Haemost. 2005; 3(Suppl.1): P0838.
- Siegmund B, Richter H, Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits? Haemophilia. 2005; 11(6): 638–641.
- VALENTINO LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia. 2006; 12(s5): 26–31.
- Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006; 12(4): 352–362.
- Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994; 55(6): 638–648.
- Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004; 10(4): 352–359.
- Klukowska A, Łaguna P, Obitko-Płudowska A, et al. Zastosowanie aktywowanego rekombinowanego czynnika VII (rFVIIa) w leczeniu dzieci chorych na hemofilię A z wysokim mianem inhibitora. Acta Haematol Pol. 1998; 29: 401–6.
- Konkle B.A., Ebbesen L.S., Friedrich U. et al.: Secondary prophylactic treatment with rFVIIa in patients with haemophilia A or B and inhibitors with high requirements for on-demand treatment: analysis of primary endpoint and safety. Vancouver, Canada: Poster presented at: XXVII International Congress of the World Federation of Hemophilia; 21–5 May 2006.
- Saxon BR, Shanks D, Jory CB, et al. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost. 2001; 86(4): 1126–1127.
- Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia. 2005; 11(3): 203–207.
- Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia. 2006; 12(3): 218–222.
- Warrier I, Baird-Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia. 1997; 3(3): 194–198.
- Klukowska A., Łaguna P , Rawicz M. Zasady postępowania w zakładaniu cewników centralnych u chorych na wrodzone osoczowe skazy krwotoczne- doświadczenia własne Medycyna wieku Rozwojowego 2008,XII,4 II 1126-1129
- W. Kreuz, C. Escuriola Ettingshausen, V. Vdovin, N. Zozulya, First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/ von Willebrand factor concentrate in an observational immune tolerance induction study, Haemophilia. 2016; 22: 87–95.
- Evans M, Cottrell D, Shiach C. Emotional and behavioural problems and family functioning in children with haemophilia: a cross-sectional survey. Haemophilia. 2000; 6(6): 682–687.
